JPRN-UMIN000022179
Completed
未知
The prospective study of denosumab for the treatment of osteoporosis in hemodialysis patients - The effect of denosumab on hemodialysis patients with osteoporosis
Yujinkai Medical Corporation Yujin-yamazaki Hospital0 sites38 target enrollmentMay 2, 2016
ConditionsOsteoporosis
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Osteoporosis
- Sponsor
- Yujinkai Medical Corporation Yujin-yamazaki Hospital
- Enrollment
- 38
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patient who have the contraindication for denosumab
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis. FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months)Treatment of postmenopausal osteoporosisMedDRA version: 8.1 Level: LLT Classification code 10031285 Term: Osteoporosis postmenopausalEUCTR2004-000138-35-GBAmgen Inc7,869
Recruiting
Phase 2
A phase II clinical trial of denosumab treatment for advanced non-small cell lung cancer with bone metastasisnon-small cell lung cancerJPRN-UMIN000008314Dokkyo Medical University Department of Pulmonary Medicine and Clinivcal Immunology40
Completed
Not Applicable
Efficacy and safety of denosumab for the treatment of osteoporosis in patients with renal failureJPRN-UMIN000011992ephrology Center, Toranomon Hospital Nephrology Center, Toranomon Hospital Kajigaya40
Completed
Phase 2
The efficacy of the use of denosumab in the prevention of aromatase inhibitor-induced bone loss in postmenopausal women with hormone receptor-positive breast cancer who are currently on or will iniate an aromatase inhibitor in the adjuvant settingBreast CancerJPRN-UMIN000013863Department of Endocrine and breast cancer, Kyoto Prefectural University of medicine100
Completed
Phase 2
The efficacy of the use of denosumab in the prevention of aromatase inhibitor-induced bone loss in postmenopausal women with hormone receptor-positive breast cancer who are currently on or will iniate an aromatase inhibitor in the adjuvant settingbreast cancerJPRN-UMIN000027425Kyoto Prefectural Universuty of Medicine100